Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41140 | ISIN: US18978H4092 | Ticker-Symbol: BE5
Frankfurt
06.06.25 | 08:07
0,785 Euro
-8,72 % -0,075
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CNS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
CNS PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur CNS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
CNS PHARMACEUTICALS Aktie jetzt für 0€ handeln
DoCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit191In person presentation today, Thursday, June 5th at 9:30 AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire...
► Artikel lesen
16.05.CNS Pharmaceuticals reports Q1 results4
16.05.CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update300Cash expected to fund operations into the second half of 2026Advancing development strategy for lead program TPI 287 to commence Phase 2 study around year end 2025 for treatment of glioblastoma multiforme...
► Artikel lesen
15.05.CNS Pharmaceuticals, Inc. - 10-Q, Quarterly Report1
13.05.CNS Pharmaceuticals Stock Surges 36% On $5 Mln Public Offering Announcement1
13.05.CNS Pharmaceuticals sets terms for $5 million stock offering3
13.05.CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules615HOUSTON, TX / ACCESS Newswire / May 13, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary...
► Artikel lesen
13.05.Pre-market Movers: Lobo EV Technologies, CNS Pharmaceuticals, Landsea Homes, Inno Holdings, Lichen International468BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.25 A.M. ET).In the Green Lobo EV Technologies Ltd. (LOBO) is up over 160%...
► Artikel lesen
13.05.CNS Pharmaceuticals erhält Orphan-Drug-Status für Krebsmedikament7
13.05.CNS Pharmaceuticals secures orphan drug status for cancer drug2
13.05.CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287534Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that appears to cross the blood-brain barrier and has published clinical efficacy data in glioblastoma multiforme (GBM)Management...
► Artikel lesen
12.05.CNS Pharmaceuticals, Inc. - S-1/A, General form for registration of securities2
14.04.CNS Pharmaceuticals files to sell 5.22M shares of common stock, warrants1
14.04.CNS Pharmaceuticals, Inc. - S-1, General form for registration of securities2
09.04.CNS Pharmaceuticals, Inc. - 8-K, Current Report3
01.04.CNS Pharmaceuticals reports FY results2
01.04.CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports Full Year 2024 Financial Results273Company has one year of cash to fund operationsCompany advancing plans to develop TPI 287, a novel, late stage abeotaxane that is potentially blood brain barrier permeable with published clinical efficacy...
► Artikel lesen
31.03.CNS Pharmaceuticals, Inc. - 8-K, Current Report2
31.03.CNS Pharmaceuticals, Inc. - 10-K, Annual Report1
25.03.XFRA BE5: WIEDERAUFNAHME/RESUMPTION290FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
Weiter >>
64 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2